Gene therapy in prostate cancer: past, present and future
Gene therapy in prostate cancer: past, present and future
复制标题
DOI：
10.2741/2828
复制
发表时间：
2008-01-01
影响因子：
3.1
通讯作者：
Gotoh, Akinobu
中科院分区：
文献类型：
--
作者：
Shirakawa, Toshiro;Fujisawa, Masato;Gotoh, Akinobu
激素难治性前列腺癌缺乏有效的治疗方法，需要开发新的治疗方式，例如基因疗法，可以单独或与目前的治疗方式结合应用于晚期前列腺癌的治疗。自1994年以来，大约有80种前列腺癌基因治疗方案已经付诸实施。基因疗法是治疗前列腺癌的理想方法。通过血清PSA水平可准确监测病情进展，超声引导可方便局部探查，前列腺作为辅助器官具有较强的免疫原性。因此，前列腺癌基因治疗试验的数量现在正在增加。本文按时间顺序回顾了前列腺癌基因治疗的临床试验，并对未来的前景进行了展望。
The absence of effective therapies for hormone refractory prostate cancer establishes the need to develop novel therapeutic modality, such as a gene therapy, that can be applied either separately or in conjunction with current treatment modalities for the treatment of advanced prostate cancer. About 80 protocols for prostate cancer gene therapy have been practiced since 1994. The gene therapy modality is ideal for the treatment of prostate cancer. The disease progress can be precisely monitored by serum-PSA level, the local access is easy by ultra-sound guidance, and prostate as an accessory organ is highly immunogenic. Consequently, the number of prostate cancer gene therapy trials is increasing now. In this paper, we review the previous clinical trials of prostate cancer gene therapy in the chronologic order, and predict the future prospects.